Version 2.1.0.0

Abstract

Abstract: DESCRIPTION (provided by applicant): The overall goal of this project is to develop bovine and human Lactoferrins as an adjuvant to augment antibody and cell mediated immunity. We will specifically address the efficacy of Lactoferrin as an adjuvant to augment efficacy of BCG vaccination to subsequent challenge with virulent Mycobacterium tuberculosis. Improved nontoxic adjuvants, especially adjuvants capable of inducing (CM are needed for research use and for development of human and veterinary vaccines. The only adjuvant licensed for human use, alum, effectively enhances antibody formation, but is seldom effective for inducing CMI. Other adjuvants such as saponin and Complete Freund's that do induce CMI are much too toxic for use in humans and are being progressively restricted in animals. Lactoferrin is different from microbial derivative adjuvants, and from cytokines and growth factors; it is an effector molecule that directly participates in host defenses. Available evidence indicatesLactoferrin participates in the induction of immune responses, especially CMI. Preliminary studies demonstrate that lactoferrin as an adjuvant enhances delayed type hypersensitivity (DTH) in mice in a dose dependent fashion and has low toxicity. Furthermore, it induces IL-12, IL-15 and TNF-a production by macrophages thereby generating a local environment likely to push immune responses towards development of CMI.

Thesaurus Terms:
Bacillus Calmette Guerin vaccine, cellular immunity, immunologic substance development /preparation, immunomodulator, lactoferrin, vaccine development
interleukin 12, interleukin 15, tumor necrosis factor alpha, veterinary medicine
laboratory mouse

Institution:	PHARMAREVIEW CORPORATION
	13627 LA CONCHA LN
	HOUSTON, TX 77083
Fiscal Year:	2002
Department:
Project Start:	15-SEP-2002
Project End:	31-AUG-2003
ICD:	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
IRG:	ZRG1